Welcome to our dedicated page for OptimizeRx Corporation news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on OptimizeRx Corporation stock.
OptimizeRx Corporation (NASDAQ: OPRX) is a leading provider in the healthcare technology sector, offering digital health messaging solutions that enhance communication between pharmaceutical companies, healthcare providers, and patients. OptimizeRx specializes in the integration of electronic health records (EHR) to distribute financial assistance, educational materials, and clinical information directly at the point of care.
The company leverages its proprietary SampleMD and eCoupon technologies to expand the distribution of patient savings and support materials within the e-prescribing workflows of over 300,000 healthcare providers. These platforms enable healthcare providers to deliver real-time financial assistance and support to patients, thereby improving medication adherence and affordability.
OptimizeRx offers a range of products, including Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement. These solutions aim to help patients start and stay on their prescribed treatments while providing pharmaceutical companies with efficient ways to increase brand awareness and adherence.
Recently, OptimizeRx has undergone significant leadership changes. Gus Halas retired as Chairperson of the Board, succeeded by Lynn O’Connor Vos, a seasoned executive with extensive experience in healthcare IT and life sciences. Additionally, Catherine M. Klema was appointed to the Board, bringing her expertise in strategy, finance, and governance.
Financially, OptimizeRx is in a robust position. The company's revenue for FY2023 is estimated to exceed $68-$70 million, with adjusted EBITDA ranging between $3-$4 million. For 2024, the company anticipates revenue of at least $100 million due to a revised gross-to-net accounting treatment for certain revenue streams from its recent acquisition of Medicx Health.
The mission of OptimizeRx is to empower the healthcare community through innovative, tech-enabled communication solutions that improve patient care. By connecting over 60% of U.S. healthcare providers and millions of patients through its digital point-of-care network, OptimizeRx continues to deliver significant value to patients, healthcare professionals, and investors.
For more information, visit www.optimizerx.com
OptimizeRx Corp. (Nasdaq: OPRX) has been invited to present at the H.C. Wainwright BioConnect Conference, taking place virtually from January 11-14, 2021. The presentation will be available on-demand starting at 6:00 a.m. ET on January 11 and can be accessed via the conference portal and OptimizeRx’s investor relations page. CEO William Febbo will hold one-on-one virtual meetings with institutional analysts and investors, highlighting the company's expanding market due to new digital health solutions. OptimizeRx reported $34.3 million in trailing revenue for the 12 months ending September 30, 2020, marking a 44% increase from the previous year.
OptimizeRx Corp. (Nasdaq: OPRX) has been invited to the Bank of America 4th Annual HCIT and Digital Health Symposium on December 9-10, 2020. CEO William Febbo will speak on the panel discussing "Trends in Tech-Enabled Rx Supply Chain." The event will include healthcare-focused Bank of America clients and executives from various sectors, including digital health and private equity. OptimizeRx offers digital health solutions linking healthcare providers and patients, helping improve medication affordability and adherence.
OptimizeRx announces a partnership with Komodo Health to integrate its Healthcare Map with OptimizeRx's digital health platform. This collaboration aims to enhance real-world evidence delivery to healthcare providers, expanding OptimizeRx's audience and improving care through actionable insights. As the COVID-19 pandemic has changed care delivery, the partnership focuses on addressing gaps in timely information for healthcare providers. OptimizeRx aims to leverage this integration to bolster patient and physician experiences, ultimately improving treatment outcomes.
OptimizeRx Corp. (Nasdaq: OPRX) has launched an innovative enhancement to its digital health platform that utilizes real-world data (RWD) and machine learning to deliver therapeutic support directly to clinicians at critical patient care moments. This unprecedented approach aims to improve communication and data accessibility in healthcare, potentially enhancing patient outcomes, especially in complex cases like oncology. OptimizeRx emphasizes the importance of actionable data for effective treatment decisions and aims to improve healthcare systems through its AI-driven capabilities.
OptimizeRx Corp. (Nasdaq: OPRX) has reported a remarkable 217% revenue growth from 2016 to 2019, attributed to its expanding digital health platform. The company earned the 432nd spot on Deloitte’s Technology Fast 500, recognizing fast-growing tech companies in North America. CEO William Febbo emphasized the significance of their digital health solutions and a dedicated team. The recent record revenue of $10.5 million for Q3 2020, reflecting a 110% increase year-over-year, signals continued strong performance in a growing market.
OptimizeRx Corp. (Nasdaq: OPRX) has partnered with Fierce Life Sciences to host a virtual event, Innovate4Outcomes, on December 3, 2020. The event aims to address key healthcare challenges exacerbated by COVID-19, promoting collaboration among industry leaders to enhance patient outcomes. Discussions will focus on supporting providers, the role of clinicians in digital strategies, adoption of patient support programs, and leveraging social media for patient engagement. Attendance is limited to 100 participants.
OptimizeRx Corp. (Nasdaq: OPRX) has appointed Angelo Campano as senior vice president and principal of agency channels to enhance partnerships with healthcare advertising agencies. With over 15 years of experience, Campano aims to drive strategic growth at OptimizeRx, including implementing point-of-care engagement programs for targeted patient populations. His background includes significant achievements in electronic health record (EHR) workflows and marketing at Ogilvy Health. The company's digital health platform connects life sciences with healthcare providers, facilitating medication affordability for patients.
OptimizeRx Corp. (Nasdaq: OPRX) reported significant financial growth for Q3 2020, with revenue increasing by 110% to $10.5 million and gross profit up 99% to $6.0 million. Non-GAAP net income was $1.1 million or $0.07 per share. The cash balance was $12.0 million, down from $14.1 million due to higher working capital investments. The company closed additional enterprise deals worth $3.6 million and expanded its digital health network through partnerships with Higi and Epion Health. Despite a GAAP net loss of $0.3 million, management remains optimistic about future growth.
OptimizeRx Corp. (Nasdaq: OPRX) will host a conference call on November 9, 2020, to discuss its Q3 2020 results, expecting record revenue exceeding $10 million, a 100% increase from the previous year. The call will also cover the growth driven by enterprise deals and the value of its Digital Health Platform. Financial results will be released prior to the call, with a question-and-answer segment to follow. Interested parties can join via toll-free and international dial-in numbers. A replay will be available until November 30, 2020.
FAQ
What is the current stock price of OptimizeRx Corporation (OPRX)?
What is the market cap of OptimizeRx Corporation (OPRX)?
What does OptimizeRx Corporation do?
What are the main products offered by OptimizeRx?
How does OptimizeRx help patients?
Who is the current Chairperson of OptimizeRx?
What recent changes have occurred in OptimizeRx's leadership?
What are OptimizeRx's financial expectations for 2024?
How widely is OptimizeRx's technology adopted?
What is SampleMD?
Where can I find more information about OptimizeRx?
What is the mission of OptimizeRx?
